Abstract:Background: Cisplatin triggers Gasdermin E (GSDME) cleavage, causing membrane bubble formation, content release, and inflammation. Caspase-3 activation initiates GSDME cleavage, and thus inhibiting this pathway mitigates cisplatin-induced pyroptosis in hepatocytes. This study aimed to delve into how cisplatin induces liver injury via pyroptosis. Methods: For animal experiments, C57BL/6J mice were divided into three groups: control, liver injury model group, and Ac-DMLD-CMK (caspase-3 inhibitor) intervention group. The liver histology was evaluated by hematoxylin and eosin staining, immunohistochemistry, immunofluorescence and TUNEL staining. The mRNA and protein levels were detected by real-time polymerase chain reaction (PCR) and Western blot analysis. For in vitro experiments, HL-7702 cells were treated with cisplatin or GSDME siRNA. Cell pyroptosis was determined via cellular morphology, cytotoxicity and viability detection, flow cytometric assay, and Western blot detection for the expression of pyroptosis-related proteins. Results: Cisplatin-induced distinct liver morphological changes, hepatocellular injury, and inflammation in mice, along with elevated serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels and increased pro-inflammatory cytokine expression. Heightened macrophage infiltration and hepatocellular death indicated cisplatin-induced hepatotoxicity. Cisplatin upregulated GSDME activation, along with Bax-mediated caspase-3 cleavage both in vivo and in vitro, implicating caspase-3/GSDME-dependent pyroptosis in liver injury. Treatment with Ac-DMLD-CMK ameliorated cisplatin-induced liver injury, reducing hepatocellular lesions, serum ALT and AST levels, cytokine expression, macrophage infiltration, and hepatocyte death. Ac-DMLD-CMK also attenuated GSDME-dependent pyroptosis post-cisplatin induction, as evidenced by decreased GSDME expression, Bax upregulation, and cleaved caspase-3 activation. For HL-7702 cells, GSDME siRNA transfection reduced GSDME expression, attenuated typical signs of cisplatin-induced pyroptosis, partially restored cell viability, and significantly inhibited cytotoxicity and a decrease in the proportion of propidium iodide-positive cells, indicating protection against cisplatin-induced hepatocyte pyroptosis. Conclusion: Our study underscores the role of the caspase-3/GSDME signaling pathway in mediating cisplatin-induced hepatotoxicity, particularly in cases of excessive or cumulative cisplatin exposure. These findings suggest that targeting GSDME could represent a promising therapeutic approach to mitigate cisplatin-induced liver damage.

Cisplatin Induces Apoptosis of Hepatocellular Carcinoma LM3 Cells Via Down-Regulation of XIAP.

Targeting NF-κB/AP-2β Signaling to Enhance Antitumor Activity of Cisplatin by Melatonin in Hepatocellular Carcinoma Cells.

Oxaliplatin Induces Apoptosis in Hepatocellular Carcinoma Cells and Inhibits Tumor Growth

Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.

Cisplatin Induces HepG2 Cell Cycle Arrest Through Targeting Specific Long Noncoding RNAs and the P53 Signaling Pathway

Receptor Interacting Protein Kinase 3 Promotes Cisplatin-Induced Necroptosis in Apoptosis-Resistant HepG2/DDP Cells.

Inhibition of PI3K/mTOR Increased the Sensitivity of Hepatocellular Carcinoma Cells to Cisplatin Via Interference with Mitochondrial-Lysosomal Crosstalk.

The Apoptosis of Non-Small Cell Lung Cancer Induced by Cisplatin Through Modulation of STIM1

Smad3 Sensitizes Hepatocelluar Carcinoma Cells to Cisplatin by Repressing Phosphorylation of Akt

Lysophosphatidic Acid Inhibits Apoptosis Induced by Cisplatin in Cervical Cancer Cells

Effects of down-regulating expression of X-linked inhibitor of apoptosis on chemotherapy induced apoptosis of gastric cancer cells

TIMP-3 Increases the Chemosensitivity of Laryngeal Carcinoma to Cisplatin Via Facilitating Mitochondria-Dependent Apoptosis.

Cisplatin induces acute liver injury by triggering caspase-3/GSDME-mediated cell pyroptosis

CXCL12 Suppresses Cisplatin-Induced Apoptosis Through Activation of JAK2/STAT3 Signaling in Human Non-Small-cell Lung Cancer Cells

Inhibition Of Autophagy Promotes Cisplatin-Induced Apoptotic Cell Death Through Atg5 And Beclin 1 In A549 Human Lung Cancer Cells

Apaf1 nanoLuc biosensors identified lentinan as a potent synergizer of cisplatin in targeting hepatocellular carcinoma cells

Mir-497 Induces Hepatocellular Carcinoma Cell Lm3 Apoptosis Through Downregulating Xiap

Cisplatin Increased the Expression of PD-1 and PD-L1 by YAP1 in Hepatocellular Carcinoma

CXCL12 suppresses cisplatin-induced apoptosis through activation of JAK2/STAT3 signaling in human non-small-cell lung cancer cells.

Luteinizing Hormone Inhibits Cisplatin-Induced Apoptosis in Human Epithelial Ovarian Cancer Cells

[Effects of NF-kappaB Inhibitor on Cisplatin-Induced Apoptosis in Cervical Cancer].